Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

Abstract Background Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the low to moderate quality of the generated evidence, safety concerns and restricted pr...

Description complète

Détails bibliographiques

Auteurs principaux:	Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-01-01
Collection:	Cardio-Oncology
Sujets:	Diffuse large B-Cell lymphoma R-CHOP chemotherapy Anthracyclines Dexrazoxane Cardiotoxicity Randomized Controlled Trial
Accès en ligne:	https://doi.org/10.1186/s40959-025-00303-y
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!